p-nitrobenzyl 2-bromo-2-methylpropionate | 84208-33-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-nitrobenzyl 2-bromo-2-methylpropionate
• 英文别名: 4-nitrobenzyl α-bromoisobutyrate；p-nitrobenzyl α-bromoisobutyrate；p-nitrobenzyl-2-bromo-2-methyl propionate；(4-Nitrophenyl)methyl 2-bromo-2-methylpropanoate
• CAS: 84208-33-3
• 化学式: C₁₁H₁₂BrNO₄
• 分子量: 302.125
• InChiKey: PWQRRDRMTKNUMF-UHFFFAOYSA-N

物化性质

• 沸点：
  377.6±22.0 °C(Predicted)
• 密度：
  1.508±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  p-nitrobenzyl 2-bromo-2-methylpropionate 在 sodium hydroxide 、 五氯化磷 、 碳酸氢钠 、 potassium carbonate 、 一水合肼 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 42.0h， 生成 cis-3-<2-(2-chloroacetamidothiazol-4-yl)-(Z)-2-<1-methyl-1-(4-nitrobenzyloxycarbonyl)ethoxyimino>acetamido>-4-methoxycarbonyl-2-azetidinone
  参考文献：
  名称：

  Chemical modification of sulfazecin. Synthesis of 4-methoxycarbonyl-2-azetidinone-1-sulfonic acid derivatives.

  摘要：

  在磺扎西丁的化学修饰过程中，从顺式-1-(2,4-二甲氧基苄基)-4-甲氧羰基-3-酞酰亚胺基-2-氮杂环丁酮(2)出发，合成了3-[2-(2-氨基噻唑-4-基)-(Z)-2-(取代氧亚胺基)乙酰胺基]-4-甲氧羰基-2-氮杂环丁酮-1-磺酸。这些新的4-取代衍生物对革兰氏阴性菌的抗菌活性比相应的4-未取代化合物更强，其中具有3,4-顺式立体化学结构的衍生物比反式异构体更活跃，尤其对铜绿假单胞菌和一些产生β-内酰胺酶的细菌更为有效。研究了用于制备2的环加成反应的报道程序;通过使用20%过量的三乙胺，可以很容易地以72%的产率得到无色晶体2。在这种环加成反应中形成β-内酰胺的可能中间体——酰基亚胺盐(6)被分离为晶体，并通过与1,8-二氮杂双环[5.4.0]-7-十一碳烯处理转化为β-内酰胺。

  DOI：

  10.1248/cpb.32.2646
• 作为产物：
  描述：

  对硝基苯甲醇 、 2-溴-2-甲基丙酰溴 在 吡啶 作用下， 以 乙醚 为溶剂， 反应 5.0h， 以29.6 g的产率得到p-nitrobenzyl 2-bromo-2-methylpropionate
  参考文献：
  名称：

  Chemical modification of sulfazecin. Synthesis of 4-methoxycarbonyl-2-azetidinone-1-sulfonic acid derivatives.

  摘要：

  在磺扎西丁的化学修饰过程中，从顺式-1-(2,4-二甲氧基苄基)-4-甲氧羰基-3-酞酰亚胺基-2-氮杂环丁酮(2)出发，合成了3-[2-(2-氨基噻唑-4-基)-(Z)-2-(取代氧亚胺基)乙酰胺基]-4-甲氧羰基-2-氮杂环丁酮-1-磺酸。这些新的4-取代衍生物对革兰氏阴性菌的抗菌活性比相应的4-未取代化合物更强，其中具有3,4-顺式立体化学结构的衍生物比反式异构体更活跃，尤其对铜绿假单胞菌和一些产生β-内酰胺酶的细菌更为有效。研究了用于制备2的环加成反应的报道程序;通过使用20%过量的三乙胺，可以很容易地以72%的产率得到无色晶体2。在这种环加成反应中形成β-内酰胺的可能中间体——酰基亚胺盐(6)被分离为晶体，并通过与1,8-二氮杂双环[5.4.0]-7-十一碳烯处理转化为β-内酰胺。

  DOI：

  10.1248/cpb.32.2646

文献信息

• 1-Sulfo-2-oxoazetidine derivatives and their production
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04550105A1

  公开（公告）日：1985-10-29

  Disclosed are compounds of the general formula: ##STR1## wherein R.sub.1 is amino, an acylated amino or a protected amino group, X is hydrogen or methoxy, and R' is hydrogen, R or R.sup.4 wherein R is an organic residue attached to the azetidine ring through a carbon atom therein and R.sub.4 is azido, a halogen, an amino group which may optionally be acylated or a group of the formula --OR.sub.5, ##STR2## or --S--S--R.sub.5 wherein R.sub.5 is an organic residue and n is 0, 1 or 2, and pharmaceutically acceptable salts and esters thereof. The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.

  揭示了一般式为：其中R₁为氨基、酰化氨基或保护氨基，X为氢或甲氧基，R'为氢、R或R⁴，其中R为有机残基，通过其中的碳原子连接到氮杂环上，R⁴为叠氮基、卤素、氨基（可选地酰化）或具有如下结构的基团--OR₅，或--S--S--R₅，其中R₅为有机残基，n为0、1或2，以及其药学上可接受的盐和酯。这些化合物具有抗微生物和/或β-内酰胺酶抑制活性，并且作为人类和驯养动物的药物具有价值。
• 1-sulfo-2-oxoazetidine derivatives and their production
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04782147A1

  公开（公告）日：1988-11-01

  Disclosed are compounds of the general formula: ##STR1## wherein R.sub.1 is amino, an acylated amino or a protected amino group, X is hydrogen or methoxy, and R' is hydrogen, R or R.sup.4 wherein R is an organic residue attached to the azetidine ring through a carbon atom therein and R.sub.4 is azido, a halogen, an amino group which may optionally be acylated or a group of the formula ##STR2## wherein R.sub.5 is an organic residue and n is 0, 1 or 2, and pharmaceutically acceptable salts and esters thereof. The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.

  揭示了一般式化合物：##STR1## 其中 R.sub.1 是氨基、酰化氨基或保护氨基，X 是氢或甲氧基，而 R' 是氢、R 或 R.sup.4，其中 R 是通过其中的一个碳原子连接到环的有机残基，而 R.sub.4 是偶氮基、卤素、氨基（可选地酰化）或式 ##STR2## 其中 R.sub.5 是有机残基，n 为 0、1 或 2，以及其药学上可接受的盐和酯。这些化合物具有抗微生物和/或β-内酰胺酶抑制活性，并且作为人类和驯化动物的药物具有价值。
• Process for the manufacture of 1-sulpho-2-oxoazetidine carboxylic acid
  申请人：Hoffmann-La Roche Inc.

  公开号：US04652651A1

  公开（公告）日：1987-03-24

  The manufacture of 1-sulpho-2-oxazetidine derivatives of the formula ##STR1## in which Het is an optionally amino-substituted, 5- or 6-membered, aromatic heterocycle containing 1 or 2 nitrogen atoms and optionally also an oxygen or sulphur atom, R.sup.1 is hydrogen, lower alkyl, phenyl-lower alkyl, lower alkanoyl, lower alkoxycarbonyl, lower alkenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, phenyl-lower-alkoxycarbonyl-lower alkyl, nitrophenyl-lower-alkoxycarbonyl-lower alkyl or carboxy-lower alkyl and R.sup.2 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxycarbonyl, lower alkanoyloxy-lower alkyl, lower alkoxycarbonyl-lower alkenyl, hydroxyiminomethyl, lower alkoxyiminomethyl, carbamoyl, carbamoyl-lower alkenyl or carbamoyloxy-lower alkyl, the group .dbd.NOR.sup.1 being present at least partially in the syn-form, in racemic form or in the form of the 3S-enantiomer, and of readily hydrolyzable esters and pharmaceutically compatible salts of these compounds, by acylating a compound of the formula ##STR2## in which R.sup.20 equals R.sup.2 or can also represent a 2,2-dimethyl-1,3-dioxolan-4-yl group and R.sup.3 is hydrogen or sulpho, or a salt thereof with a thioester of the formula ##STR3## in which Het is as above and R.sup.10 has any of the values of R.sup.1 except carboxy-lower alkyl, and can also represent a tri-lower alkyl-silyl-lower-alkoxycarbonyl-lower alkyl group or a carboxy-lower alkyl group converted into a readily hydrolyzable ester group, and the group .dbd.NOR.sup.10 is present at least partially in the syn-form, and carrying out subsequent steps (N-sulphonation, conversion of R.sup.20 into R.sup.2, R.sup.10 into R.sup.1), some of which are optional. The invention also provides certain novel products of formula I and benzthiazolyl thioesters of formula III per se and the preparation of the benzthiazolyl thioesters by esterifying corresponding carboxylic acids. Finally, the invention provides a process for the preparation of carboxylic acids in which R.sup.1 is t-alkoxycarbonylmethyl. The compounds of formula I have antimicrobial activity.

  该专利描述了一种制备1-磺酸-2-噁唑环丙烷衍生物的方法，其化学式为##STR1##其中Het是一个含有1或2个氮原子和可能还有一个氧原子或硫原子的可选氨基取代的5或6元芳香杂环，R.sup.1是氢、低烷基、苯基-低烷基、低烷酰、低烷氧羰基、低烯基-低烷基、低烷氧羰基-低烷基、苯基-低烷氧羰基-低烷基、硝基苯基-低烷氧羰基-低烷基或羧基-低烷基，R.sup.2是氢、低烷基、低烯基、低炔基、低烷氧羰基、低烷酰氧基-低烷基、低烷氧羰基-低烯基、羟基亚胺甲基、低烷氧亚胺甲基、氨甲酰基、氨甲酰基-低烯基或氨甲酰氧基-低烷基，.dbd.NOR.sup.1基团至少部分以syn-形式存在，是外消旋形式或3S-对映体形式，以及这些化合物的易水解酯和药用兼容盐的制备方法。
• On the pH sensitive optoelectronic properties of amphiphilic reduced graphene oxide via grafting of poly(dimethylaminoethyl methacrylate): a signature of p- and n-type doping
  作者：Atanu Kuila、Nabasmita Maity、Rama K. Layek、Arun K. Nandi

  DOI：10.1039/c4ta03408b

  日期：——

  Poly(N,N′-dimethylaminoethyl methacraylate) (PDMAEMA) functionalized reduced graphene oxide (rGO) is synthesized by atom transfer radical polymerization, followed by attachment to rGO via diazonium coupling. The rGO-PDMAEMA (RGP) is characterized by 1H NMR, UV-Vis, FTIR and Raman spectroscopy. TEM and AFM studies demonstrate the formation of molecular brushes of PDMAEMA chains over rGO surface, and the TGA thermograms indicate 55 wt% grafting of PDMAEMA. RGP is dispersible in the widest spectrum of solvents from CCl4 to water [solubility parameter (δp + δh), 0.6 to 58]. RGP exhibits strongly pH dependent fluorescence properties: at pH 4, it exhibits two emission peaks, but at pH 7 and pH 9.2, a single and broad emission peak is observed. Two emission peaks at pH 4 are attributed to radiative decay of excitons to two kinds of holes in the rGO originating from illumination and p-type doping, which is also characterized by a blue shift of the Raman D band. Moreover, n-type doping of RGP at pH 9.2 is also evident due to a similar Raman shift. The dc-conductivity of RGP at pH 4 is 2 orders higher than that of pH 9.2 and the I–V characteristic curve at pH 7 exhibits a bimodal NDR property with a rectification ratio of 5.5. The bimodal NDR property is explained with a model using density of states and polaronic band.

  聚(N,N'-二甲基氨基乙基甲基丙烯酸酯) (PDMAEMA) 功能化还原氧化石墨烯 (rGO) 通过原子转移自由基聚合合成，然后通过重氮偶联连接到 rGO。 rGO-PDMAEMA (RGP) 通过 1H NMR、UV-Vis、FTIR 和拉曼光谱进行表征。 TEM 和 AFM 研究表明在 rGO 表面上形成了 PDMAEMA 链的分子刷，TGA 热分析图表明 PDMAEMA 接枝率为 55 wt%。 RGP 可分散在最广泛的溶剂中，从 CCl4 到水 [溶解度参数 (δp + δh)，0.6 至 58]。 RGP 表现出强烈的 pH 依赖性荧光特性：在 pH 4 时，它表现出两个发射峰，但在 pH 7 和 pH 9.2 时，观察到单个且宽的发射峰。 pH 4 时的两个发射峰归因于激子对 rGO 中两种空穴的辐射衰变，这两种空穴源自照明和 p 型掺杂，其特征还在于拉曼 D 带的蓝移。此外，由于类似的拉曼位移，RGP 在 pH 9.2 时的 n 型掺杂也很明显。 RGP 在 pH 4 时的直流电导率比 pH 9.2 时高 2 个数量级，pH 7 时的 I-V 特性曲线表现出双峰 NDR 特性，整流比为 5.5。双峰 NDR 特性通过使用态密度和极化带的模型进行解释。
• 1-sulfo-2-oxozetidine derivatives and their product ion
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04822788A1

  公开（公告）日：1989-04-18

  Disclosed are compounds of the general formula: ##STR1## wherein R.sub.1 is amino, an acylated amino or a protected amino group, X is hydrogen or methoxy, and R' is hydrogen, R or R.sup.4 wherein R is an organic residue attached to the azetidine ring through a carbon atom therein and R.sub.4 is azido, a halogen, an amino group which may optionally be acylated or a group of the formula ##STR2## wherein R.sub.5 is an organic residue and n is 0, 1 or 2, and pharmeceutically acceptable salts and esters thereof. The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.

  本发明涉及一般式为：##STR1##的化合物，其中R.sub.1是氨基，酰化氨基或保护氨基基团，X是氢或甲氧基，R'是氢，R或R.sup.4，其中R是通过其中的一个碳原子连接到氮杂四元环上的有机残基，R.sub.4是偶氮基，卤素，氨基（可以选择性地酰化）或式子##STR2##中的基团，其中R.sub.5是有机残基，n为0、1或2，以及其药学上可接受的盐和酯。这些化合物具有抗微生物和/或β-内酰胺酶抑制活性，是人类和家畜的有价值的药物。